Development of Dengue Vaccine. Phase 2.
Final rept. 15 Sep 89-14 Sep 90,
HAWAII BIOTECHNOLOGY GROUP INC AIEA
Pagination or Media Count:
Work has been in four areas subcloning of NS1, characterization of anti-D3 human sera, subcloning of E, and expression of dengue proteinspeptides. Four HaeIII fragments subclones in lambda gtll have been identified in the correct orientation Hae272, Hae166, Hae415 and Hae113. Alterations in the Western protocol have resulted in successful Western analysis with human sera. Several attempts to subclone various large fragments of the E gene into pSS20 have been unsuccessful. Lysogens of the complete NS1 gene and a truncated E have been generated and shown to produce the expected fusion proteins.
- Genetic Engineering and Molecular Biology